Mr. Mathers has served as a member of our Board of Directors since March 2013. He joined NEA as a partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Ra Pharmaceuticals, Envisia Therapeutics, Synlogic, Lumos Pharma, Amplyx Pharmaceuticals, Senti Biosciences, Inozyme Pharma, Reneo Pharmaceuticals, Akouos, Mirum Pharmaceuticals, Trevi Therapeutics, Curzian, and ObsEva. Previously, he was a board member of Lumena Pharmaceuticals (sold to Shire), Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), Intarcia Therapeutics, Satori Pharmaceuticals, Liquidia, Southeast BIO, MedImmune, and the Biotechnology Innovation Organization (BIO). Prior to joining NEA, Mr. Mathers most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor’s degree in chemistry from North Carolina State University.